Kempharm, Inc (KMPH) SEC Filing 8-K Material Event for the period ending Monday, May 4, 2020

Kempharm, Inc

CIK: 1434647 Ticker: KMPH

View differences made from one to another to evaluate Kempharm, Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Kempharm, Inc.


Assess how Kempharm, Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Kempharm, Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Kempharm, Inc provided additional information to their SEC Filing as exhibits

Ticker: KMPH
CIK: 1434647
Form Type: 8-K Corporate News
Accession Number: 0001437749-20-009196
Submitted to the SEC: Mon May 04 2020 8:05:51 AM EST
Accepted by the SEC: Mon May 04 2020
Period: Monday, May 4, 2020
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Other Events
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: